Skandinaviska Enskilda Banken Ab (Publ) Corcept Therapeutics Inc Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 09, 2023	SELL	$21.97 - $33.8 $197,730 - $304,200	-9,000 Reduced 17.11%	43,600 $1.19 Million
Q2 2023 Aug 07, 2023	SELL	$21.44 - $25.15 $1.15 Million - $1.35 Million	-53,500 Reduced 50.42%	52,600 $1.17 Million
Q1 2023 May 11, 2023	BUY	$19.2 - $24.47 $2.04 Million - $2.6 Million	106,100 New	106,100 $2.3 Million
Q2 2021 Aug 10, 2021	SELL	$19.97 - $24.43 $455,316 - $557,004	-22,800 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$23.49 - $30.56 $91,611 - $119,184	-3,900 Reduced 14.61%	22,800 $542,000
Q4 2020 Feb 11, 2021	SELL	$16.78 - $27.3 $1.3 Million - $2.11 Million	-77,200 Reduced 74.3%	26,700 $698,000
Q3 2020 Nov 12, 2020	BUY	$12.46 - $19.98 $401,212 - $643,356	32,200 Added 44.91%	103,900 $1.81 Million
Q2 2020 Aug 13, 2020	BUY	$11.0 - $18.26 $788,700 - $1.31 Million	71,700 New	71,700 $1.21 Million

403

84.3M

1.04M

1.33M

Ticker CORT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,105,000
Market Cap $6.81B
Description
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients ...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.